The risk of developing multiple sclerosis (MS) is highest in the month of April, and lowest in October, indicates an analysis of the available evidence, published online in the Journal of Neurology Neurosurgery and Psychiatry.
Nov 14, 2012
0
0
Australian researchers have made the significant discovery that loss of a twin during very early pregnancy explains the increased risk of birth defects seen in multiple pregnancies after infertility treatment.
Jul 5, 2011
0
0
With 3,284 cycles using frozen eggs, Italy is the leader in Europe, the 27th Annual Meeting of the European Society of Human Reproduction and Embryology heard Wednesday.
Jul 6, 2011
0
0
A University of Birmingham fetal medicine expert has helped to shape new advice from NICE on antenatal care for women pregnant with twins or triplets. Professor Mark Kilby says the new guideline, published today (September ...
Sep 28, 2011
0
0
Research presented today at the American Society for Reproductive Medicine (ASRM) by scientists from the University of Colorado and Duke University concludes that fresh donor eggs during in vitro fertilization (IVF) provide ...
Nov 1, 2017
0
0
A new technique successfully used in mice to identify embryos likely to result in a successful pregnancy could be used in humans, potentially boosting IVF success rates and helping to reduce the number of multiple births ...
Jan 3, 2012
0
0
(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).
Sep 13, 2012
0
0
Elsevier announced the publication of several commentaries in the scientific journal Reproductive BioMedicine Online on the subject of how many embryos it is safe and proper to place in a uterus, and how best to regulate ...
Jul 26, 2011
0
0
Over the past two decades, the frozen preservation of embryos has become routine practice in IVF. What currently happens to embryos next is controlled by overlapping and complicated rules that confuse and disempower IVF users.
May 13, 2013
0
0
(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.
Feb 9, 2013
0
0
